Vincerx Pharma, Inc. Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Vincerx Pharma, Inc. announced a poster presentation of preclinical data of Vincerx's proprietary payload and linker technology and VIP943, the Company's internalizing ADC targeting CD123, at the 64(th) American Society of Hematology (ASH) Annual Meeting 2022. VIP943 is a novel ADC, which binds to the IL3-receptor alpha chain (CD123). VIP943 combines the unique payload class of kinesin spindle protein inhibitors (KSPi) with a proprietary legumain-cleavable linker.

Vincerx's CellTrapper(TM) modification of the KSPi prevents diffusion out of the cell, allowing intracellular accumulation. The nonpermeability of the payload prevents off-target toxicities, leading to favorable efficacy and safety profiles.